Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

Author(s): Yuechi Sun, Yan He, Yuan Liu, Guixiu Shi

Journal Name: Current Pharmaceutical Biotechnology

Volume 15 , Issue 6 , 2014

Become EABM
Become Reviewer
Call for Editor


Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.

Keywords: Biologics, dermatomyositis, interstitial lung disease, polymyositis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 10 September, 2014
Page: [521 - 524]
Pages: 4
DOI: 10.2174/138920101506140910145940
Price: $65

Article Metrics

PDF: 69